Table 2.
Treatment coverage for MDA campaign rounds–program, epidemiologic and survey
| Category | Round 1 | Round 2 | Round 3 | Round 4 | ||||
|---|---|---|---|---|---|---|---|---|
| fMDA | MDA | fMDA | MDA | fMDA | MDA | fMDA | MDA | |
| MDA campaign data | ||||||||
| Total households visited | 17,704 | 18,237 | 14,610 | 14,584 | 18,004 | 17,528 | 16,050 | 15,257 |
| Community health worker enumerated population (a) | 95,214 | 90,347 | 79,518 | 70,305 | 88,605 | 90,077 | 81,208 | 79,653 |
| Total courses of dihydroartemisinin–piperaquine administered (b) | 25,372 | 78,591 | 17,092 | 56,620 | 14,599 | 72,006 | 8,256 | 64,285 |
| Program coverage (%) | 26.6 | 87.0 | 21.5 | 80.5 | 16.5 | 79.9 | 10.2 | 80.7 |
| Capture–recapture–based adjustments | ||||||||
| Number of households not visited | 5,797 | 4,750 | 8,891 | 8,403 | 5,497 | 5,459 | 7,451 | 7,730 |
| Imputed population not listed (c) | 29,565 | 24,225 | 45,344 | 42,855 | 28,035 | 27,841 | 38,000 | 39,423 |
| Epidemiologic coverage* (%) (d) | 20.3 | 68.6 | 13.7 | 50.0 | 12.5 | 61.1 | 6.9 | 54.0 |
| Survey data | ||||||||
| Number surveyed | – | – | 1,644 | 2,472 | – | – | 1,137 | 2,050 |
| Survey coverage (95% CI) | – | – | 31.9% (22.0–43.8) | 83.2% (77.2–87.9) | – | – | 11.4% (4.2–27.6) | 88.0% (85.6–90.0) |
fMDA = focal MDA; MDA = mass drug administration.
*
d = b/a + c.